Tetragastrin

L-Tryptophyl-L-methionyl-L-aspartyl-L-phenylalaninamide. The C-terminal tetrapeptide of gastrin. It is the smallest peptide fragment of gastrin which has the same physiological and pharmacological activity as gastrin.

Also Known As:

AOC-Tetragastrin; AOC-Tetrapeptide; CCK (30-33); CKK-4; Cholecystokinin (30-33); Cholecystokinin 4; AOC Tetragastrin; AOC Tetrapeptide; Cholecystokinin Tetrapeptide; Tetrapeptide, Gastrin; CCK-4; Cholecystokinin-Tetrapeptide; Gastrin Tetrapeptide; L-Phenylalaninamide, L-tryptophyl-L-methionyl-L-alpha-aspartyl-

Networked: 135 relevant articles (6 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rupprecht, Rainer: 7 articles (01/2011 - 02/2003)
2.	Shlik, Jakov: 6 articles (07/2013 - 08/2002)
3.	Eser, Daniela: 6 articles (01/2011 - 01/2005)
4.	Ströhle, Andreas: 5 articles (01/2012 - 02/2003)
5.	Schüle, Cornelius: 5 articles (01/2011 - 01/2005)
6.	Rupprecht, R: 5 articles (06/2009 - 03/2000)
7.	Maron, Eduard: 4 articles (07/2013 - 07/2004)
8.	Tõru, Innar: 4 articles (07/2013 - 07/2004)
9.	Vasar, Veiko: 4 articles (07/2013 - 07/2004)
10.	Bradwejn, J: 4 articles (09/2012 - 01/2001)

Related Diseases

1.	Neoplasms (Cancer) 02/15/1988 - "Prolonged administration of tetragastrin resulted in a significant reduction of the incidence and number of colonic tumors per rat in the group given the fiber-free diet. " 09/01/1986 - "Administration of tetragastrin also significantly decreased the incidences and/or numbers of colonic tumors in Wk 20 and 35. " 06/01/1985 - "Thus tetragastrin had no promoting effect on colonic tumors." 09/15/1990 - "The effect of tetragastrin on pancreatic tumors induced by azaserine was investigated in Wistar rats. " 02/15/1988 - "However, administration of tetragastrin had little or no influence on the incidence, number or histology of colonic tumors in the group given basal diet plus wheat bran. "
2.	Stomach Neoplasms (Stomach Cancer) 02/15/1990 - "At week 52, prolonged administration of tetragastrin alone resulted in a significant reduction in the incidence and number of gastric cancers and a significant increase or decrease in the labelling indices of the fundic and antral mucosae, respectively. " 03/01/1989 - "Three hundred and one gastric cancer patients have been examined preoperatively to investigate their gastric acid secretions after stimulation by tetragastrin, and serum gastrin stimulation by a test meal, as well as for skin reactions and an evaluation of their serum glycoproteins. " 03/01/1985 - "In view of the anomalous expression of blood group and related antigens in the gastric mucosae of patients with malignant and premalignant diseases of the stomach, and the potential clinical value of their measurement, a preliminary study has been performed on the blood group antigens A, B, H, Lea, Leb, and I(Ma) in glycoprotein rich extracts of the resting and tetragastrin stimulated gastric juice of patients without evidence of gastric cancer. " 02/15/1990 - "The effects of combined administration of tetragastrin and the ornithine decarboxylase inhibitor 1,3-diaminopropane (DAP) on the incidence and number of gastric cancers induced by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), and the BUdR labelling indices of the fundic and antral mucosae, were investigated in inbred Wistar rats. " 07/15/1982 - "Five gastro-entero-pancreatic hormones or related peptides (tetragastrin, glucagon, secretin, cholecystokinin-pancreozymin and cerulein) significantly increased the number of stomach cancer cells from 15% to 310% of the number of control cells cultivated in a serum-free, hormone-free medium. "
3.	Gastritis 08/01/1997 - "IL-1 beta release was significantly greater in patients with enlarged fold gastritis, significantly correlated with both basal and tetragastrin-stimulated acid outputs in the H. " 11/01/1999 - "In addition, the basal acid output and tetragastrin stimulated maximal acid output increased significantly from 0.5 (0.5) to 4.1 (1.5) mmol/h and from 2.5 (1.2) to 13.8 (0.7) mmol/h (p<0.01), and fasting serum gastrin concentrations decreased significantly from 213.5 (31.6) to 70.2 (7.5) pg/ml (p<0.01) after eradication in patients with enlarged fold gastritis. "
4.	Metaplasia 05/15/1988 - "The prolonged administration of tetragastrin in depot form from 1 week after NaOH treatment resulted in a significant increase in basal gastric acid secretion and a significant reduction in the incidence and number of intestinal metaplasia in experiment week 35. " 05/15/1988 - "These results show that the prolonged administration of tetragastrin to rats after NaOH treatment increases gastric acid secretion and suppresses the induction of intestinal metaplasia." 05/15/1988 - "Only goblet cell metaplasia was found in rats treated with tetragastrin. " 05/15/1988 - "Inhibitory effect of prolonged administration of tetragastrin on experimentally induced intestinal metaplasia in Wistar rats." 05/15/1988 - "The effect of tetragastrin on the induction of intestinal metaplasia by intragastric administration of 5% NaOH solution was investigated in Wistar rats. "
5.	Panic Disorder (Panic Attack) 01/01/2009 - "Experimental panic induction with cholecystokinin-tetrapeptide (CCK-4) has been established as a model to study the pathophysiology of panic disorder. " 01/01/2001 - "This study was designed to examine the sensitivity of different sleep stages to the pharmacological provocation of nocturnal panic attacks by cholecystokinin tetrapeptide (CCK-4). " 11/01/1997 - "This study suggests that treatment with an SSRI can reduce an enhanced sensitivity to CCK-4 without modifying cardiovascular and neuroendocrine responses to CCK-4 in patients with panic disorder." 09/01/1997 - "Patients with panic disorder (DSM-III-R) were given 50 micrograms CCK-4 i.v. at 1100 hours on 2 separate study days. " 11/15/1992 - "The findings of this study suggest that a dose of 20 micrograms of CCK-4 (ED75) might be suitable for efficacy studies of CCKB antagonists and other potential antipanic drugs in patients with panic disorder."

Related Drugs and Biologics

1.	Methylnitronitrosoguanidine (MNNG)
2.	Histamine (Histamine Dihydrochloride)
3.	Acids
4.	Antral
5.	Interleukin-1beta (Interleukin 1 beta)
6.	Anti-Anxiety Agents (Anxiolytics)
7.	Cholecystokinin (Pancreozymin)
8.	Carbon Dioxide
9.	Bethanechol (Duvoid)
10.	Lactic Acid (Lactate)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Proximal Gastric Vagotomy
3.	Truncal Vagotomy
4.	Injections
5.	Intravenous Injections